Drug intelligence / Profile preview

CAY004

Development stage: Preclinical
Lead developer: Cayuga Biotech

Overview

CAY004 is an early-stage therapeutic candidate currently in the discovery phase, developed by Cayuga Biotech. As of early 2024, the specific indication, molecular target, and modality for CAY004 remain undisclosed by the company. Cayuga Biotech generally focuses on developing novel hemostatic agents and therapies for bleeding disorders, often leveraging polyphosphate-based technologies, though it is not explicitly confirmed if CAY004 utilizes this specific platform.

Beyond the preview

Go deeper on CAY004.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CAY004.

Explore the full profile